Aqua Bounty Technologies

Aqua Bounty Technologies is a biotechnology company focused on improving productivity in commercial aquaculture, a $60-billion industry undergoing rapid expansion worldwide. Our objective is to apply revolutionary discoveries in the life-sciences to transform the economics of seafood production by radically shortening production horizons and extending yields through the use of leading edge molecular technologies. Aqua Bounty Technologies, Inc. (the “Parent”) was incorporated in December 1991 in the state of Delaware for the purpose of conducting research and development of the commercial viability of a group of proteins commonly known as antifreeze proteins (AFPs). In 1996, the Parent obtained the exclusive licensing rights for a gene construct (transgene) used to create a breed of farm-raised salmon that are expected to exhibit growth rates substantially faster than natural growth rates.

Aqua Bounty Canada, Inc. (the “Canadian Subsidiary”) was incorporated in January 1994 in Canada for the purpose of establishing a commercial biotechnology laboratory to produce antifreeze proteins and to conduct research and development programs related to the commercialization of cryopreservatives and the antifreeze gene construct.

Aqua Bounty Pacific, Inc., (the “U.S. Subsidiary”) was incorporated in September 2002 in the state of California for the purpose of developing products for the shrimp aquaculture industry, including therapeutics, vaccines and genetically improved brood stock. In late 2004, the U.S. Subsidiary commenced sales of the Company’s first commercial product which is designed to increase the growth rate and disease resistance of shrimp. In October 2006, the U.S. Subsidiary was merged into the Parent and ceased to operate as a separate legal entity.

The Company maintains modern biotechnology laboratories at St. John’s and San Diego, and operates a modern fish hatchery on a 3.5 acre site on Prince Edward Island. This facility, with a present capacity of 100,000 smolt, is one of the few certified disease-free aquaculture facilities in Atlantic Canada, a regulatory status that will allow ABT to export fish eggs, milt and fry to most countries of the world.